Scientists Creating ‘Cancer Vaccine’ That Could Potentially Stop the Disease ‘20 Years Early'

Last updated on 8 JUL 2025

Scientists at the University of Oxford and pharmaceutical company GSK have collaborated to develop a revolutionary cancer vaccine. The vaccine aims to prevent cancer up to 20 years before it develops. This collaborative effort targets cells at the pre-cancerous stage when cancer is typically undetectable. Professor Sarah Blagden, director of the partnership, explains that cancer can take up to two decades to fully develop. During this time, cells undergo a transition from normal to cancerous. By identifying and targeting these transitioning cells, researchers aim to create a vaccine that stops cancer in its tracks long before symptoms appear. GSK has committed £50 million over three years to fund this innovative research program. Scientists will use cutting-edge technology to detect previously undetectable cellular changes in pre-cancerous cells, pinpointing vulnerabilities. This approach marks a significant shift from treating established cancer to preventing its development altogether.

Cancer’s Devastating Impact in the US and UK

Cancer’s toll in the United States is staggering. The National Cancer Institute reports that in 2024, doctors diagnosed over 2 million new cancer cases. Tragically, 611,720 Americans died from the disease that same year. Breast cancer, prostate cancer, lung cancer, and colorectal cancer rank among the most common types. Melanoma, bladder cancer, kidney cancer, non-Hodgkin lymphoma, and several others also impact thousands of lives. In the United Kingdom, the numbers paint an equally grim picture. More than 385,000 people receive a cancer diagnosis each year. Cancer claims approximately 167,000 lives annually across the UK. Researchers at Oxford and GSK aim to reduce these devastating statistics dramatically. Their collaboration focuses on developing a vaccine to prevent cancer from gaining a foothold in the first place. By targeting pre-cancerous changes, they hope to stop the disease before it starts.

The Oxford-GSK Cancer Vaccine Partnership

Prof Blagden explained that cancer doesn’t develop overnight. Normal cells can take up to 20 years or more to turn cancerous. During this lengthy transition, most cancers remain invisible. Researchers call this the “pre-cancer stage.” According to E. Shelley Hwang of Duke University School of Medicine: ‘’Many solid tumors have an identifiable “pre-cancer” stage where groups of cells appear histologically abnormal but have limited potential to progress to the point where they can cause local symptoms, disseminated disease, or death.’’ Cells undergo changes that put them on the path to becoming malignant. However, these changes are not detectable with current screening methods. Oxford and GSK’s vaccine aims to target cells at this early stage. By identifying and acting on pre-cancerous changes, they hope to prevent cancer from developing at all. Several technological breakthroughs have made this approach possible. “We’re lucky because there have been a huge amount of technical breakthroughs that mean we can …. start to be able to detect the undetectable,” she said. “And from that, we’ve been able to work out what features those cells have as they’re transitioning towards cancer, and so we can design a vaccine speficially targeted towards that,” said Prof Blagden. These advances allow researchers to “detect the undetectable.” The team has determined what features to target by studying cells in the pre-cancer stage. They can then design a vaccine to act on those vulnerabilities specifically. If successful, this approach could revolutionize cancer prevention. Stopping the disease before it starts would save millions of lives worldwide.

Detecting the “Undetectable”

Cancer development is a slow process, often taking up to 20 years for normal cells to become cancerous. During this lengthy transition, most cancers remain invisible to current detection methods. Scientists call this period the “pre-cancer stage.” “You always imagine it would take about a year or two years to develop in your body but, in fact, we now know that cancers can take up to 20 years, sometimes even more, to develop – as a normal cell transitions to become cancerous,” prof Blagden told BBC’s Radio 4 on Monday.Researchers aim to create a vaccine targeting this pre-cancer stage rather than fighting established cancer. They hope to stop cancer before it fully forms by focusing on these early cellular changes. Recent technological breakthroughs have made it possible to detect previously unseen pre-cancer vulnerabilities. These advances allow scientists to identify specific features of cells as they transition towards cancer. With this knowledge, they can design vaccines to target these early-stage changes. “We can start to be able to detect the undetectable,” says Professor Blagden. “From that, we’ve been able to work out what features those cells have as they’re transitioning towards cancer, and so we can design a vaccine specifically targeted towards that.” This approach marks a significant shift in cancer prevention. Instead of waiting for cancer to develop and then treating it, scientists are working to stop it before it starts. By targeting the earliest stages of cancer development, this vaccine could potentially save countless lives and reduce the need for aggressive cancer treatments.

Additional Potential Cancer Vaccines in Development

University of Oxford researchers are developing other potential cancer vaccines in collaboration with GSK. These vaccines target specific types of cancer or high-risk groups. LynchVax aims to help people with Lynch syndrome, a genetic disorder that increases the risk of certain cancers. This vaccine could potentially prevent or delay the onset of cancer in individuals with the Lynch syndrome gene mutation. OvarianVax focuses on early-stage ovarian cancer. It works by training the immune system to recognize and attack cancer cells in their earliest stages of development. Early detection and prevention are crucial for ovarian cancer, which often goes undiagnosed until later stages. LungVax targets individuals at high risk for specific types of lung cancer. By identifying those most likely to develop lung cancer, this vaccine could offer a preventative option before the disease takes hold. These targeted vaccines represent a shift in cancer prevention strategies. Instead of a one-size-fits-all approach, researchers are developing vaccines tailored to specific cancer types and risk factors. This personalized approach could lead to more effective prevention methods for different groups of people.

A New Era in Cancer Prevention

The potential impact of the GSK-Oxford cancer vaccine research extends far beyond the lab. If successful, this preventative approach could drastically reduce cancer rates, ease the burden on healthcare systems, and improve the quality of life for millions. While challenges remain in identifying all relevant pre-cancer markers and ensuring vaccine safety across diverse populations, the promise of personalized prevention drives researchers forward. We may see a shift in medical focus from treatment to early intervention. Though it may take years for these vaccines to become widely available, ongoing clinical trials offer hope. Each step brings us closer to a future where many forms of cancer could become preventable diseases. As Prof Blagden states, we stand at the threshold of a new era in cancer prevention, one that could fundamentally change our approach to this devastating illness.

Some of the links I post on this site are affiliate links. If you go through them to make a purchase, I will earn a small commission (at no additional cost to you). However, note that I’m recommending these products because of their quality and that I have good experience using them, not because of the commission to be made.